Free Access
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
Page(s) 16 - 19
Section M/S revues
Published online 15 November 2005
  1. Futerman AH, Van Meer G. The cell biology of lysosomal storage disease. Nat Rev Mol Cell Biol 2004; 5 : 554–65. [Google Scholar]
  2. Raas-Rothschild A, Pankova-Kholmyansky I, Kacher Y, Futerman AH. Glycosphingolipidoses: beyond the enzymatic defect. Glycoconj J 2004 ; 21 : 295–304. [Google Scholar]
  3. de Duve C. Exploring cells with a centrifuge. Science 1975; 189 : 186–94. [Google Scholar]
  4. Ginzburg L, Kacher Y, Futerman AH. The pathogenesis of glycosphingolipid storage disorders. Semin Cell Dev Biol 2004; 5 : 417–31. [Google Scholar]
  5. Korkotian E, Schwarz A, Pelled D, et al. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J Biol Chem 1999; 274 : 21673–8. [Google Scholar]
  6. Pelled D, Shogomori H, Futerman AH. The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase. J Inherit Metab Dis 2000; 23 : 175–84. [Google Scholar]
  7. Lloyd-Evans E, Pelled D, Riebeling C, et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J Biol Chem 2003 ; 278 : 23594–9. [Google Scholar]
  8. Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky, E, Schiffmann R, Futerman AH. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis 2005; 18 : 83–8. [Google Scholar]
  9. Pelled D, Lloyd-Evans E, Riebeling C, et al. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J Biol Chem 2003; 278 : 29496–501. [Google Scholar]
  10. Lachmann RH. Miglustat. Oxford GlycoSciences/Actelion. Curr Opin Investig Drugs 2003; 4 : 472–9. [Google Scholar]
  11. Jeyakumar M, Butters TD, Cortina-Borja M, et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA 1999; 96 : 6388–93. [Google Scholar]
  12. Ginzburg L, Futerman AH. Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease. J Neurochem 2005 (sous presse). [Google Scholar]
  13. Tessitore A, del P Martin M, Sano R, et al. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol Cell 2004; 15 : 753–66. [Google Scholar]
  14. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. Ann Rev Genom Hum Genet 2003; 4 : 403–36. [Google Scholar]
  15. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet 2002; 3 : 954–66. [Google Scholar]
  16. Futerman AH, Sussman JL, Horowitz M, et al. New directions in the treatment of Gaucher disease. Trends Pharmacol Sci 2004; 25 : 147–51. [Google Scholar]
  17. Dvir H, Harel M, McCarthy AA, et al. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep 2003; 4 : 704–9. [Google Scholar]
  18. Premkumar L, Sawkar AR, Boldin-Adamsky S, et al. X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease. J Biol Chem 2005; 280 : 23815–9. [Google Scholar]
  19. Fan JQ. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci 2003; 24 : 355–60. [Google Scholar]
  20. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355 : 1481–5. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.